Athersys, Inc. (ATHX) news stock charts
Athersys, Inc. (ATHX) Investment Summary:
We are a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple diseases. In 2007, we advanced our lead program for treating obesity into clinical development. We also advanced two additional programs in 2007, receiving authorization for Investigational New Drug applications, or INDs, for treatment of acute myocardial infarction, or AMI, and the complications (e.g., graft versus host disease) associated with hematopoietic stem cell/bone marrow transplantation for certain hematologic malignancies. We have additional programs in discovery and preclinical development for the treatment of ischemic stroke and certain cognitive or attention disorders. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0000950152-08-001952.html#FIS_BUSINESS"www.athersys.com
35 Employees
Founded in 1995
ATHERSYS INC (ATHX:NASDAQ)
LAST $2.67 USD
CHANGE TODAY -0.07 -2.55%
VOLUME 47.5K
As of 11:07 AM 03/22/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ATHERSYS INC (ATHX)
|
OPEN
$2.75
|
PREVIOUS CLOSE
$2.74
|
|
|
DAY HIGH
$2.75
|
DAY LOW
$2.59
|
|
|
52 WEEK HIGH
12/23/09 - $6.40
|
52 WEEK LOW
03/24/09 - $0.71
|
|
|
MARKET CAP
50.5M
|
AVERAGE VOLUME 10 D
324.9K
|
|
|
EPS TTM
$-0.81
|
SHARES OUTSTANDING
18.9M
|
|
|
ATHX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stocks on the Move: Aetna, E*Trade, Intel, MetroPCS
12/21/2009 10:37 AM ET
Plus more stocks making headlines in Monday's market
Key developments for ATHERSYS INC (ATHX)
Athersys, Inc. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 11, 2010).
03/11/2010
Athersys, Inc. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 11, 2010).
Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009
03/11/2010
Athersys, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported net loss attributable to common stockholders of $5,014,000 or $0.26 per basic and diluted share on total revenues of $869,000 compared to net loss attributable to common stockholders of $4,713,000 or $0.25 per basic and diluted share on total revenues of $259,000 for the same period of last year. Loss from operations was $4,934,000 compared to $4,890,000 for the same period of last year. For the year, the company reported net loss attributable to common stockholders of $15,366,000 or $0.81 per basic and diluted share on total revenues of $2,159,000 compared to net loss attributable to common stockholders of $17,992,000 or $0.95 per basic and diluted share on total revenues of $3,105,000 for the same period of last year. Loss from operations was $15,615,000 compared to $19,092,000 for the same period of last year.
Athersys, Inc. to Report Q4, 2009 Results on 03/11/2010
02/25/2010
Athersys, Inc. announced that they will report Q4, 2009 results on 03/11/2010
Athersys, Inc. financial resources
ATHX Competitors
| Company | Last | Change |
| Aastrom Biosciences Inc | $1.77 USD | +0.05 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | ATHX | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ATHX |
||
|
ATHX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Athersys, Inc.
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
2010-03-12 07:18:38
Quote: Results of Operations and Financial Condition.
On March 11, 2010, Athersys, Inc. issued a press release announcing financial
results for its fourth quarter ended December 31, 2009. A copy of this press
release is attached hereto as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is being furnished to the Securities and
Exchange Commission and shall not be deemed to be "filed" for the purposes of
Section ...Read article
Skymark Research Initiates Independent Research Coverage on Athersys, Inc.
2010-03-05 02:15:39
Quote: 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Athersys, Inc. (: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and ...Read article
Athersys to Host Fourth Quarter Financial Results Call
2010-03-05 02:15:36
Quote: Press ReleaseSource: Athersys, Inc.On Thursday February 25, 2010, 4:00 pm ESTCLEVELAND, Feb. 25, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (: -Investors and other interested parties are invited to listen to the conference call by dialing 800-273-1254 in the U.S. and Canada, 973-638-3440 from abroad, or via a live Internet broadcast at the Company's website atAthersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to...Read article
Athersys to Host Fourth Quarter Financial Results Call
2010-02-26 07:40:49
Quote: Press ReleaseSource: Athersys, Inc.On Thursday February 25, 2010, 4:00 pm ESTCLEVELAND, Feb. 25, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: -Investors and other interested parties are invited to listen to the conference call by dialing 800-273-1254 in the U.S. and Canada, 973-638-3440 from abroad, or via a live Internet broadcast at the Company's website atAthersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates desig...Read article
Skymark Research Initiates Independent Research Coverage on Athersys, Inc.
2010-02-25 03:37:14
Quote: 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Athersys, Inc. (Nasdaq: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentar...Read article
Athersys to Present at 12th Annual BIO CEO & Investor Conference
2010-02-25 03:37:14
Quote: Press ReleaseSource: Athersys, Inc.On Tuesday February 2, 2010, 11:00 am ESTCLEVELAND, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: -Dr. Gil Van Bokkelen, chairman and chief executive officer, is scheduled to present on Monday, February 8, 2010, at 1:00 p.m. EST. Investors and other interested parties may listen to a live, audio webcast at:Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The ...Read article
Skymark Research Initiates Independent Research Coverage on Athersys, Inc.
2010-02-04 02:17:45
Quote: 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Athersys, Inc. (Nasdaq: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentar...Read article
Athersys to Present at 12th Annual BIO CEO & Investor Conference
2010-02-04 02:17:45
Quote: Press ReleaseSource: Athersys, Inc.On Tuesday February 2, 2010, 11:00 am ESTCLEVELAND, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: -Dr. Gil Van Bokkelen, chairman and chief executive officer, is scheduled to present on Monday, February 8, 2010, at 1:00 p.m. EST. Investors and other interested parties may listen to a live, audio webcast at:Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The ...Read article
Athersys to Present at 12th Annual BIO CEO & Investor Conference
2010-02-03 02:14:12
Quote: Press ReleaseSource: Athersys, Inc.On Tuesday February 2, 2010, 11:00 am ESTCLEVELAND, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: -Dr. Gil Van Bokkelen, chairman and chief executive officer, is scheduled to present on Monday, February 8, 2010, at 1:00 p.m. EST. Investors and other interested parties may listen to a live, audio webcast at:Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The ...Read article
Athersys Files Shelf Registration Statement
2010-01-26 02:28:55
Quote: In addition, when available, copies of the prospectus, and any prospectus supplement relating to a particular offering, may be obtained by contacting Athersys, Inc., attention: Laura Campbell, 3201 Carnegie Avenue, Cleveland, Ohio 44115-2634, lcampbell@athersys.com.
About Athersys
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing Mu...Read article
Athersys Files Shelf Registration Statement
2010-01-15 02:35:46
Quote: In addition, when available, copies of the prospectus, and any prospectus supplement relating to a particular offering, may be obtained by contacting Athersys, Inc., attention: Laura Campbell, 3201 Carnegie Avenue, Cleveland, Ohio 44115-2634, lcampbell@athersys.com.
About Athersys
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing Mu...Read article
ATHERSYS, INC / NEW Files SEC form 8-K, Change in Directors or Principal Officers
2009-12-25 03:14:38
Quote: ATHERSYS, INC / NEWRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
ATHERSYS, INC / NEW
24-Dec-2009Change in Directors or Principal OfficersPrivacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incompleteness...Read article
Athersys to Host Second Quarter 2009 Financial Results Call
2009-11-30 02:58:01
Quote: and Canada, or 706-645-9291 from abroad, and entering access code 20479176.
About Athersys, Inc.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem(r), a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncolog...Read article
Athersys Reports 2009 First Quarter Results
2009-11-30 02:58:01
Quote: Partners included in the CSCRM consortium are the Cleveland Clinic, University Hospitals, Case Western Reserve University, the Ohio State University and Athersys, as well as other organizations. Approximately $800,000 of the funding is directly aimed at supporting activities at the Company involving administration of MultiStem in the oncology and pulmonary areas.
Histamine H3 Receptor Antagonist Program
In addition to the stem cell and regenerative medicine programs at the Company, Athersys is...Read article
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 02:58:01
Quote: Results of Operations and Financial Condition.
On May 7, 2009, Athersys, Inc. issued a press release announcing financial
results for its first quarter ended March 31, 2009. A copy of this press release
is attached hereto as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is being furnished to the Securities and
Exchange Commission and shall not be deemed to be "filed" for the purposes of
Section 18 of...Read article
Athersys Reports 2009 Second Quarter Results
2009-11-30 02:58:00
Quote: and Canada, or 706-645-9291 from abroad, and entering access code 20479176.
About Athersys, Inc.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology s...Read article
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 02:58:00
Quote: Results of Operations and Financial Condition.
On August 6, 2009, Athersys, Inc. issued a press release announcing financial
results for its second quarter ended June 30, 2009. A copy of this press release
is attached hereto as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is being furnished to the Securities and
Exchange Commission and shall not be deemed to be "filed" for the purposes of
Section 18...Read article
Athersys Reports 2009 Third Quarter Results
2009-11-30 02:57:58
Quote: and Canada, or 706-645-9291 from abroad, and entering access code 36174982.
About Athersys, Inc.
www.athersys.com.
http://www.globenewswire.com/newsroom/prs/?pkgid=4548
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our...Read article
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
2009-11-30 02:57:58
Quote: Results of Operations and Financial Condition.
On November 5, 2009, Athersys, Inc. issued a press release announcing financial
results for its third quarter ended September 30, 2009. A copy of this press
release is attached hereto as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is being furnished to the Securities and
Exchange Commission and shall not be deemed to be "filed" for the purposes of
Sectio...Read article
Would you like to leave a comment about Athersys, Inc. ATHX
Find out what social network information about Athersys, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Athersys, Inc.'s Stock there is more great penny stock and market information at Realpennies